Pharmaceuticals News and Research

RSS

Hologic second quarter revenues increase 7.4% to $471.2 million

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its results for the second fiscal quarter ended March 24, 2012.

From Hologic, Inc. 30 Apr 2012

MDGHA, CHAI and Mylan partner to fight childhood deaths caused by diarrhea

Mylan Laboratories Limited, the Indian subsidiary of Mylan Inc., today announced that it has entered into a partnership with the United Nation's Millennium Development Goals Health Alliance (MDGHA) and the Clinton Health Access Initiative (CHAI) to fight childhood deaths caused by diarrhea.

30 Apr 2012

UCSD researchers analyze landscape of smoking cessation over the past 20 years

Smoking is a major public health issue and quitting is the single most important thing smokers can do to improve their health. In the 2012 edition of the prestigious Annual Review of Public Health, researchers at the University of California, San Diego School of Medicine have reviewed the landscape of smoking cessation over the past 20 years.

30 Apr 2012

Only few clinical trials are being conducted to test drugs in pediatric patients

Although children are more likely than adults to suffer from many diseases, few clinical trials are being conducted to test drugs in pediatric patients, according to a study to be presented Saturday, April 28, at the Pediatric Academic Societies (PAS) annual meeting in Boston.

30 Apr 2012

U.S. District Court rules in favor of Merck over ZETIA and VYTORIN patent litigation

Merck, known as MSD outside the United States and Canada, announced today that the U.S. District Court for the District of New Jersey has ruled in Merck's favor in two jointly related patent infringement suits against Mylan Pharmaceuticals Inc.

30 Apr 2012

McKesson to settle Medicaid billing lawsuit

The Justice Department says the prescription drug distributor overcharged Medicaid.

27 Apr 2012

Highlights: Cuomo's plan for out-of-network charges runs into trouble; Federal agents seize patient records in Houston mental hospital

Today's news on local health policy issues comes from New York, Connecticut, Mississippi, Colorado, Iowa, Texas, North Carolina and Kansas.

27 Apr 2012

First Edition: April 27, 2012

Today's headlines include details of a new study finding that, as a result of the health law, consumers and businesses will receive an estimated $1.3 billion in rebates from insurance companies this year.

27 Apr 2012

Simulations Plus launches new version of GastroPlus simulation software

Simulations Plus, Inc., a leading provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, announced today the release of Version 8.0 of its flagship GastroPlus simulation software with significantly expanded functionality and user convenience.

27 Apr 2012

FDA ODAC to review Onyx’s NDA for carfilzomib

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the company's new drug application (NDA) for carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies. ODAC will review carfilzomib at its meeting on June 20, 2012.

27 Apr 2012

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.

27 Apr 2012

New URMC trial to evaluate carvedilol for high blood pressure

Researchers at the University of Rochester Medical Center are testing whether different doses of an established blood pressure medication can provide the same benefits as a standard dose in people with mild hypertension, possibly with fewer side effects and at a lower cost. The newly launched clinical trial, funded with a $1.9 million grant from the National Heart Lung and Blood Institute, is the first of its kind in the United States.

27 Apr 2012

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Shire plc, the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder.

27 Apr 2012

Watson enters definitive agreement to acquire Actavis

Watson Pharmaceuticals, Inc. and Actavis Group today jointly announced that Watson has entered into a definitive agreement to acquire privately held Actavis for approximately EUR4.25 billion upfront.

27 Apr 2012

Boehringer Ingelheim selects Veeva as global CRM provider

Boehringer Ingelheim, a Top 20 global pharmaceutical company has selected Veeva CRM, including iRep for the iPad, for global deployment supporting its prescription medicine commercial and medical teams.

26 Apr 2012

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas (PDA) who have progressed after receiving two prior therapies.

26 Apr 2012

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.

26 Apr 2012

ASIA honors SCI researchers with 2012 Apple Award

American Spinal Injury Association (ASIA) has awarded its 2012 Apple Award to the article by Mark Nash, PhD, et al, entitled, "Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial."

26 Apr 2012

Gender differences in musculoskeletal health are not solely due to hormones

Osteoarthritis, osteoporosis, fractures, and spinal disorders are among the most common reasons for doctor visits. These conditions have more than one thing in common: they are all musculoskeletal problems and are more prevalent in women.

26 Apr 2012

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.

26 Apr 2012